| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Christos Pantelis | Q5113577 |
| Patrick McGorry | Q7147153 | ||
| Dan I. Lubman | Q37838458 | ||
| Stephen J Wood | Q42733695 | ||
| Murat Yücel | Q43643566 | ||
| Sue M Cotton | Q44137880 | ||
| Nadia Solowij | Q46973260 | ||
| Emre Bora | Q56928700 | ||
| Warrick J Brewer | Q114422725 | ||
| Michael J. Takagi | Q114427360 | ||
| P2093 | author name string | Alex Fornito | |
| Philippe Conus | |||
| P2860 | cites work | Reasons for increased substance use in psychosis | Q22252274 |
| Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review | Q28238516 | ||
| Causal association between cannabis and psychosis: examination of the evidence | Q28241735 | ||
| Specific impairments of planning | Q28260771 | ||
| The positive and negative syndrome scale (PANSS) for schizophrenia | Q28301751 | ||
| Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction | Q30053550 | ||
| Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date | Q31084441 | ||
| Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? | Q31095554 | ||
| Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders | Q31106608 | ||
| The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? | Q31149257 | ||
| Development and validation of MIX: comprehensive free software for meta-analysis of causal research data | Q33260285 | ||
| Dose-related neurocognitive effects of marijuana use. | Q33962455 | ||
| Cannabis as a risk factor for psychosis: systematic review | Q33986870 | ||
| Chlorpromazine equivalent doses for the newer atypical antipsychotics | Q34208233 | ||
| Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study | Q34220050 | ||
| Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis | Q34235419 | ||
| Planning and spatial working memory following frontal lobe lesions in man. | Q34279238 | ||
| Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. | Q34309398 | ||
| Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. | Q34397288 | ||
| Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction | Q34415424 | ||
| Residual neuropsychologic effects of cannabis | Q34438024 | ||
| Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective | Q34509505 | ||
| Cannabis use and age at onset of schizophrenia | Q34545981 | ||
| Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis | Q34589855 | ||
| Regional brain abnormalities associated with long-term heavy cannabis use. | Q34592700 | ||
| Cannabis use and the risk of later schizophrenia: a review | Q35720869 | ||
| The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues | Q36965847 | ||
| Substance-induced psychosis: a diagnostic conundrum | Q37085918 | ||
| Cannabis, cannabinoids and schizophrenia: integration of the evidence | Q37160448 | ||
| Cannabis use and cognition in schizophrenia | Q37643444 | ||
| Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study | Q39680990 | ||
| The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. | Q40176239 | ||
| Substance use disorders in schizophrenia--clinical implications of comorbidity | Q43145195 | ||
| The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness | Q43639398 | ||
| Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders | Q43969348 | ||
| Medication adherence of individuals with a first episode of psychosis | Q44133367 | ||
| Early-onset cannabis use and cognitive deficits: what is the nature of the association? | Q44360031 | ||
| Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. | Q44413284 | ||
| Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up | Q44537020 | ||
| Impact of cannabis and other drugs on age at onset of psychosis. | Q45168263 | ||
| Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. | Q45930302 | ||
| Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. | Q46013619 | ||
| The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning | Q46066974 | ||
| Fewer neurological soft signs among first episode psychosis patients with heavy cannabis use. | Q46355590 | ||
| The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis | Q46578593 | ||
| Familial psychopathology in the First Episode Psychosis Outcome Study | Q46809084 | ||
| Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study | Q48280427 | ||
| Increased duration of illness is associated with reduced volume in right medial temporal/anterior cingulate grey matter in patients with chronic schizophrenia | Q48519567 | ||
| The deficit syndrome in the Suffolk County Mental Health Project | Q48779127 | ||
| The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. | Q50651673 | ||
| Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. | Q51861083 | ||
| Cognitive functioning in children and adolescents in their first episode of psychosis: differences between previous cannabis users and nonusers. | Q51887191 | ||
| Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. | Q51888329 | ||
| Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. | Q51915513 | ||
| Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. | Q51934012 | ||
| The role of cannabis in cognitive functioning of patients with schizophrenia. | Q51957715 | ||
| Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. | Q51969760 | ||
| CANTAB explicit memory is less impaired in addicted schizophrenia patients. | Q51991798 | ||
| Spatial working memory ability is a marker of risk-for-psychosis. | Q52004869 | ||
| Cognitive functioning of long-term heavy cannabis users seeking treatment. | Q52014109 | ||
| The Trail Making Test as an initial screening procedure for neuropsychological impairment in older children. | Q52092345 | ||
| Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. | Q52926271 | ||
| Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. | Q55056971 | ||
| Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics | Q55969829 | ||
| The relationship between non-acute adolescent cannabis use and cognition | Q56909749 | ||
| Cannabis use and outcome of recent onset psychosis | Q57403352 | ||
| The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia | Q57709578 | ||
| Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia | Q58190172 | ||
| Do cognitive impairments recover following cessation of cannabis use ? | Q60630751 | ||
| Computerized assessment in neuropsychiatry using CANTAB: discussion paper | Q68205413 | ||
| Cannabis abuse and the course of recent-onset schizophrenic disorders | Q72371028 | ||
| Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis | Q80574459 | ||
| Comorbid substance-use in schizophrenia: relation to positive and negative symptoms | Q83915156 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| meta-analysis | Q815382 | ||
| P304 | page(s) | 316-330 | |
| P577 | publication date | 2010-07-25 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample | |
| P478 | volume | 38 |
| Q35356756 | AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder |
| Q30417841 | Acute administration of Δ⁹ tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice |
| Q38379526 | Adolescent Initiation of Cannabis Use and Early-Onset Psychosis |
| Q55617842 | Age at Onset and Social Cognitive Impairment in Clinically Stabilized Patients with Schizophrenia: An Ecological Cross-Sectional Study. |
| Q35955940 | Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample |
| Q37497599 | An FMRI study of the influence of a history of substance abuse on working memory-related brain activation in schizophrenia |
| Q36354947 | An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use. |
| Q38619670 | Applying Behavior Change Theories and Qualitative Methods in Substance Misuse Implementation Research: Conceptualizing the Adoption of Breaking Free Online in Real-World Clinical Practice |
| Q52625218 | Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. |
| Q58714618 | Assessment of Cognition in Schizophrenia Using Trail Making Test: A Meta-Analysis |
| Q52600030 | Associations between adolescent cannabis use and brain structure in psychosis. |
| Q34530176 | BRIEF REPORT: THE IMPACT OF ALCOHOL AND CANNABIS MISUSE ON COGNITION AMONG INDIVIDUALS WITH SCHIZOPHRENIA. |
| Q35536880 | Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. |
| Q47274758 | Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders |
| Q36157669 | Cannabinoids and Schizophrenia: Risks and Therapeutic Potential |
| Q36817167 | Cannabis Use Is Associated With Increased Psychotic Symptoms and Poorer Psychosocial Functioning in First-Episode Psychosis: A Report From the UK National EDEN Study |
| Q50993509 | Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. |
| Q38950359 | Cannabis and development of dual diagnoses: A literature review |
| Q50434552 | Cannabis use and cognitive function in first episode psychosis: differential effect of heavy use. |
| Q44906174 | Cannabis use and cognitive functions in at-risk mental state and first episode psychosis |
| Q41498847 | Cannabis use in male and female first episode of non-affective psychosis patients: Long-term clinical, neuropsychological and functional differences |
| Q97596506 | Cannabis use in patients with early psychosis is associated with alterations in putamen and thalamic shape |
| Q35984216 | Cannabis-related episodic memory deficits and hippocampal morphological differences in healthy individuals and schizophrenia subjects |
| Q37598266 | Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects. |
| Q35019827 | Cognitive Enhancement Therapy in substance misusing schizophrenia: results of an 18-month feasibility trial |
| Q38887606 | Cognitive Function in Individuals With Psychosis: Moderation by Adolescent Cannabis Use. |
| Q44741809 | Cognitive alterations in patients with non-affective psychotic disorder and their unaffected siblings and parents |
| Q35534902 | Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. |
| Q47197065 | Cognitive deficits and ethnicity: a cohort study of early psychosis patients in The Netherlands |
| Q39452682 | Cognitive development prior to onset of psychosis |
| Q47945952 | Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls |
| Q90867980 | Cognitive impairment from early to middle adulthood in patients with affective and nonaffective psychotic disorders |
| Q38124448 | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings |
| Q41040248 | Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis |
| Q58599983 | Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel Treatments |
| Q38700007 | Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. |
| Q60630719 | Delayed preattentional functioning in early psychosis patients with cannabis use |
| Q90263481 | Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model |
| Q50652382 | Drugs and psychosis ... and now for some good news. |
| Q64261741 | Early Somatosensory Processing Over Time in Individuals at Risk to Develop Psychosis |
| Q92238326 | Early Substance Use Cessation Improves Cognition-10 Years Outcome in First-Episode Psychosis Patients |
| Q47739996 | Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls |
| Q39340879 | Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia |
| Q33836425 | Electroencephalographic abnormalities and 5-year outcome in first-episode psychosis |
| Q37285509 | Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis |
| Q26865311 | Gone to Pot - A Review of the Association between Cannabis and Psychosis |
| Q47439536 | Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype? |
| Q35213673 | How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library |
| Q36577094 | Inferior performance on selected neuropsychological tests in abstinent schizophrenia patients who have used cannabis. |
| Q34080360 | Internet addictive individuals share impulsivity and executive dysfunction with alcohol-dependent patients |
| Q34521105 | Keep off the grass? Cannabis, cognition and addiction |
| Q43872699 | Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings. |
| Q37358080 | MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse |
| Q94544886 | Metaphor Processing Dysfunctions in Schizophrenia Patients With and Without Substance Use Disorders |
| Q26830827 | Mismatch negativity: translating the potential |
| Q47375879 | Motivational changes of cannabis use prior to and during the course of schizophrenia |
| Q33762494 | Neurocognitive functioning of individuals with schizophrenia: using and not using drugs |
| Q50645808 | Neurodevelopmental origin of cognitive impairment in schizophrenia. |
| Q36101350 | Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History |
| Q34378233 | Pathways from cannabis to psychosis: a review of the evidence |
| Q36815675 | Patterns of Substance Use During Cognitive Enhancement Therapy: An 18-Month Randomized Feasibility Study |
| Q33904544 | Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder |
| Q38996589 | Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders |
| Q36281966 | Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome |
| Q48135332 | Psychosocial functioning in first-episode psychosis and associations with neurocognition, social cognition, psychotic and affective symptoms |
| Q35301038 | Social functioning trajectories of young first-episode psychosis patients with and without cannabis misuse: a 30-month follow-up study. |
| Q44530576 | Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial |
| Q26859349 | Substance use in clinical high risk for psychosis: a review of the literature |
| Q36591245 | Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia |
| Q38192896 | Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. |
| Q37597632 | THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. |
| Q34531537 | The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability |
| Q38882225 | The Effect of Changes in Cannabis Exposure on Psychotic Symptoms in Patients With Comorbid Cannabis Use Disorder |
| Q52861250 | The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis. |
| Q36386484 | The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia |
| Q40401198 | The Search for Environmental Mechanisms Underlying the Expression of Psychosis: Introduction |
| Q88271142 | The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial |
| Q50562471 | The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis. |
| Q37061404 | The neural correlates of mental rotation abilities in cannabis-abusing patients with schizophrenia: an FMRI study |
| Q55397242 | Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. |
| Q45767391 | Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors |
| Q38639956 | Understanding marijuana's effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A pilot investigation. |
| Q27303941 | Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medications |
| Q52303742 | [Clinical prognosis of schizophrenic patients with cannabis addiction. Between nihilism and hope]. |
| Q86423209 | [First-episode psychosis, cognitive difficulties and remediation] |
Search more.